Perceptive Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Perceptive Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,000	Closed	-$3.13M	–	115
2023 Q3	$3.13M	Buy	+100,000	New	+$11.3M	0.1%	78
2019 Q2	–	Sell	-100,000	Closed	-$421K	–	117
2019 Q1	$421K	Buy	+100,000	New	+$12.9M	0.01%	94
2016 Q3	–	Sell	-979,200	Closed	-$18.7M	–	213
2016 Q2	$18.7M	Buy	979,200 +429,200	+78%	+$7.95M	1.29%	18
2016 Q1	$10.7M	Buy	550,000 +50,000	+10%	+$874K	0.94%	24
2015 Q4	$19.3M	Buy	500,000 +200,000	+67%	+$6.48M	1.43%	17
2015 Q3	$9.63M	Sell	300,000 -200,000	-40%	-$6.79M	0.77%	32
2015 Q2	$15.2M	Sell	500,000 -250,000	-33%	-$5.11M	0.92%	29
2015 Q1	$9.96M	Buy	750,000 +300,000	+67%	+$4M	0.77%	33
2014 Q4	$6.51M	Sell	450,000 -800,000	-64%	-$13.5M	0.55%	45
2014 Q3	$26.4M	Buy	+1,250,000	New	+$28.2M	2.67%	11
2014 Q2	–	Sell	-350,000	Closed	-$8.41M	–	140
2014 Q1	$8.41M	Buy	+350,000	New	+$8.92M	0.88%	35
2013 Q3	–	Hold	0	–	-$10.5M	–	117
2013 Q2	–	Hold	0	–	–	–	22

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors's SRPT Position: Q2 2024 in Review

Perceptive Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 525,683 shares — an estimated $68.1M sold.

Perceptive Advisors first reported a position in SRPT in Q2 2013 and held it in 24 quarters. The position peaked at $209M in Q3 2016. 484 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

Perceptive Advisors reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
Perceptive Advisors sold 525,683 Sarepta Therapeutics shares in Q2 2024, an estimated $68.1M.
Perceptive Advisors first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 24 quarters.
Perceptive Advisors's Sarepta Therapeutics position peaked at $209M in Q3 2016.
484 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.